For instance, the first immune checkpoint inhibitor combination approved by FDA in October, 2015 for the treatment of unresectable or metastatic BRAFV600 wild-type melanoma consists of nivolumab and ipilimumab, which target the programmed cell death protein 1 and cytotoxic T lymphocyte antigen 4, respectively [34]. This evidence concerns the gene PDCD1 and melanoma.